Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terence W Friedlander

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Cancer Research|December 14, 2011
Common structural and epigenetic changes in the genome of castration-resistant prostate cancerTerence W Friedlander, Ritu Roy, Scott A Tomlins, et al.
BMC Cancer|August 30, 2020
A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancerClinton L Cario, Emmalyn Chen, Lancelote Leong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2020
Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib StudyEdwin M Posadas, Kim N Chi, Ronald de Wit, et al.
Clinical Genitourinary Cancer|October 18, 2018
Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 StudyMina Lee, Haemin Hong, Won Kim, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant RecipientsChloe E Atreya, Eric A Collisson, Meyeon Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2014
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgensWon Kim, Li Zhang, John H Wilton, et al.
Journal for Immunotherapy of Cancer|May 14, 2021
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancerMeenal Sinha, Li Zhang, Sumit Subudhi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2022
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial CancerChristopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, et al.
Future Oncology (London, England)|November 23, 2023
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumabChristopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, et al.
Cancer Immunology Research|October 1, 2016
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate CancerXiao X Wei, Stephen Chan, Serena Kwek, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Cancer Research|December 14, 2011
Common structural and epigenetic changes in the genome of castration-resistant prostate cancerTerence W Friedlander, Ritu Roy, Scott A Tomlins, et al.
BMC Cancer|August 30, 2020
A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancerClinton L Cario, Emmalyn Chen, Lancelote Leong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2020
Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib StudyEdwin M Posadas, Kim N Chi, Ronald de Wit, et al.
Clinical Genitourinary Cancer|October 18, 2018
Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 StudyMina Lee, Haemin Hong, Won Kim, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant RecipientsChloe E Atreya, Eric A Collisson, Meyeon Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2014
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgensWon Kim, Li Zhang, John H Wilton, et al.
Journal for Immunotherapy of Cancer|May 14, 2021
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancerMeenal Sinha, Li Zhang, Sumit Subudhi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2022
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial CancerChristopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, et al.
Future Oncology (London, England)|November 23, 2023
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumabChristopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, et al.
Cancer Immunology Research|October 1, 2016
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate CancerXiao X Wei, Stephen Chan, Serena Kwek, et al.
Pageof 5